FDA advisors recommend approval of Votrient (Glaxo Smith Kline) for Soft Tissue Sarcoma

The FDA's Oncologic Drugs Advisory Committee voted to support use of Votrient (pazopanib), from Glaxo Smith Kline, for patients with advanced Soft Tissue Sarcoma who have received prior chemotherapy. Data from a 369-patient study showed the drug enabled patients to live a median of 4.6 months, about 3.1 months longer than placebo, without disease progression. The trial excluded patients with gastrointestinal stromal tumours and adipocytic sarcomas and the panel were concerned about side effects. Votrient is already approved in the USA and Europe for the treatment of Advanced Renal Cell Carcinoma.